#ranbaxy

Malvinder Singh | Ranbaxy case: Malvinder Singh gives proof of financial deals with Radha Soami Satsang head

NEW DELHI: Former promoter of Ranbaxy, Malvinder Singh has filed an affidavit in the Delhi High Court detailing transaction details of loans he gave to Gurinder Singh Dhillon and his family to back his complaint against the spiritual guru.

The undertrial businessman had earlier filed a complaint against Dhillon, head of Radha Soami Satsang Beas, among others, with Delhi Police’s Economic…

Most Indian players have left Japan over the previous decade. Ranbaxy was one of the early participants.

COMPANIES NEWS:  India's biggest drugmaker, Sun Pharmaceutical Industries, is growing in the Japanese market when the greater part of its friends have demonstrated they are not bullish on it. 

Mumbai-based Lupin is Japan's 6th biggest medication generics player however it as of late said the yearly value cuts forced there had made the market ugly. It would keep on developing there however just in single-digit (in esteem terms). 

There were additionally reports that Lupin was taking a gander at selling its Japanese auxiliary, Kyowa. The organization didn't affirm any such advancement yet it had not long ago stripped the Japanese injectables business to Neo ALA Co, completely claimed auxiliary of Abu Dhabi-based Neopharma Group. Most Indian players have left Japan over the previous decade. 

Ranbaxy was one of the early contestants. It left a joint endeavor with Nippon Chemiphar in December 2009. Dr. Reddy's Laboratories, Orchid Chemicals, and Cadila Healthcare wrapped up their Japan business in the next years. 

They discovered it didn't bode well to remain put resources into an exceptionally controlled market, one where edges were relatively lower than in other created ones. 

A senior official at a pharma firm that had left its Japan business a few years before as of late portrayed to Business Standard how the administrative scene in Japan has been evolving.

Ranbaxy’s ex-promoters’ custody extended in Religare fraud case

The Hush Post | 7:55 pm | One-minute read

A Delhi court extended the judicial custody of former Ranbaxy owners Shivinder Singh and Malivnder Singh for 14 days in the Religare funds scam on Thursday.

The judicial custody of former chairman-director of Religare Finvest Sunil Godhwani, Kavi Arora and Anil Saxena is also extended till November 14.

Deepak Sehrawat, Chief Metropolitan Magistrate, will…

Former promoters of pharma major Ranbaxy, hospital chain Fortis and financial services firm Religare - Malvinder Mohan Singh and his younger brother Shivinder Mohan Singh - were arrested by the Economic Offences Wing (EoW) of Delhi Police after some high octane drama for allegedly causing wrongful loss worth Rs 2,397 crore to Religare Finvest Ltd. Shivinder was nabbed in the afternoon, while his elder brother Malvinder was arrested in Ludhiana (Punjab) late night after a brief search.

Along with the Singh brothers, the police also arrested former Religare Finvest MD Kavi Arora, and former Religare Group CFO Anil Saxena along with former Religare MD Sunil Godhwani.

A statement issued by the EOW said, "The alleged persons having absolute control on Religare Enterprises Limited (REL) and its subsidiaries put Religare Finvest Limited (RFL) in poor financial condition by way of distributing the loans to the companies having no financial standing and controlled by the alleged persons. These companies wilfully defaulted on repayments, causing a loss to RFL to the tune of Rs 2,397 crore." Read More

Ranbaxy’s Singh brothers arrested in loan fraud

The Delhi police have arrested Ranbaxy’s Singh brothers and three former executives of Religare Finvest in relation to a fraud complaint filed by the company. RFL is alleged to have made loans to group companies without taking adequate collateral when the Singhs were promoters. The borrowing firms wilfully defaulted on the loans, causing RFL a loss of ₹2,400 crore. The arrest marks an…